Crescent Biopharma (CBIO) Equity Average (2014 - 2026)

Crescent Biopharma (CBIO) has 13 years of Equity Average data on file, last reported at $193.4 million in Q1 2026.

• Equity Average for Q1 2026 came in at $193.4 million, up 947.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $193.4 million (up 947.63% YoY), and the FY2025 annual result was $93.8 million, up 717.66% from the prior year.
• Equity Average advanced to $193.4 million in Q1 2026 per CBIO's latest filing, from $159.8 million in the prior quarter.
• Over five years, Equity Average peaked at $193.4 million in Q1 2026 and troughed at -$22.8 million in Q1 2025.
• A 5-year average of $59.4 million and a median of $51.9 million in 2022 frame the typical range for Equity Average.
• On a YoY basis, Equity Average climbed as much as 2004.85% in 2025 and fell as far as 167.79% in 2025.
• A 5-year view of Equity Average shows it stood at $45.5 million in 2022, then slipped by 6.68% to $42.5 million in 2023, then plunged by 119.75% to -$8.4 million in 2024, then jumped by 2004.85% to $159.8 million in 2025, then rose by 21.02% to $193.4 million in 2026.
• Business Quant data shows CBIO's Equity Average at $193.4 million in Q1 2026, $159.8 million in Q4 2025, and $127.9 million in Q3 2025.